German firms work together on autoimmune disorders

9 January 2020

Germany’s BioMed X has unveiled a new joint research group, in collaboration with Merck KGaA (MRK: DE), the sixth such collaborative project between the two companies.

The projects are headquartered at the BioMed X Innovation Center in Heidelberg, Germany. The latest will focus on the role of the intestinal epithelial barrier in autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS).

The main goal of the new group is to understand the molecular mechanisms of the interactions between this part of the body and the immune cells involved in autoimmune diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK